tirzepatide surmount 4 for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Tirzepatide Demonstrates Sustained Weight Loss

Without those hunger cues, people find they can lose 10% of their body weight, or even more

The rise in obesity rates growth contribution during the forecast period in 2025 is 4.5%

Potential adverse effects and drug interactions: Gastrointestinal symptoms Cramping, diarrhoea, constipation, and abdominal discomfort are common, particularly at higher doses

Dahl D, Onishi Y, Norwood P et al (2022) Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial

E., Magyar, P

She highlighted prescriber-directed medication adjustmentssuch as slow dose escalation, use of the lowest therapeutic dose, microdosing/intermediate dosing, and supportive measures, such as anti-emetics/prokineticsas effective strategies for side-effect management